Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Free Report) – Stock analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Actinium Pharmaceuticals in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.20) per share for the quarter, up from their prior estimate of ($0.25). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($0.91) EPS and FY2027 earnings at ($0.67) EPS.
Separately, Stephens reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, March 31st. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $4.50.
Actinium Pharmaceuticals Stock Performance
NYSE:ATNM opened at $1.29 on Thursday. The firm’s fifty day moving average is $1.17 and its 200-day moving average is $1.28. Actinium Pharmaceuticals has a 52 week low of $0.95 and a 52 week high of $1.95. The firm has a market cap of $40.47 million, a P/E ratio of -0.93 and a beta of -0.11.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new position in Actinium Pharmaceuticals during the fourth quarter worth $89,000. Renaissance Technologies LLC boosted its stake in Actinium Pharmaceuticals by 35.4% during the fourth quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock worth $531,000 after acquiring an additional 102,154 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in Actinium Pharmaceuticals during the fourth quarter worth $96,000. AM Investment Strategies LLC bought a new position in Actinium Pharmaceuticals during the fourth quarter worth $40,000. Finally, Bailard Inc. bought a new position in Actinium Pharmaceuticals during the fourth quarter worth $79,000. 27.50% of the stock is owned by institutional investors.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.
In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.
Featured Stories
- Five stocks we like better than Actinium Pharmaceuticals
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
